Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 6

Calcitonin levels in washout samples vs. cytology in the detection of malignant lymph node metastasis in recurrent medullary thyroid cancer

Pages
3061–3066
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, for the first time, we demonstrated that the Ct-FNA/sCt ratio was a better predictor of metastatic LNs in recurrent MTC than a particular cut-off for Ct-FNA alone.Key words: Recurrent medullary thyroid cancer, fine needle aspiration cytology, calcitonin, washout sample

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Calcitonin level in fine-needle aspirate washout fluid (Ct-FNA) was extensively studied for thyroid nodules and lymph nodes (LN).
📊
Key Findings & Data:Materials and methods: The database of MTC patients between 2010 and 2021 was retrospectively reviewed.
💡
Conclusion & Impact:Furthermore, for the first time, we demonstrated that the Ct-FNA/sCt ratio was a better predictor of metastatic LNs in recurrent MTC than a particular cut-off for Ct-FNA alone.Key words: Recurrent medullary thyroid cancer, fine needle aspiration cytology, calcitonin, washout sample
🔬Design:Review & Systematic Survey
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Background/aim: Calcitonin level in fine-needle aspirate washout fluid (Ct-FNA) was extensively studied for thyroid nodules and lymph nodes (LN). However, the data was scarce for neck recurrences/metastases of medullary thyroid cancer (MTC). Thus, the diagnostic accuracy of Ct-FNA and cytology in the detection of neck LN metastases of recurrent MTC cases were assessed. Materials and methods: The database of MTC patients between 2010 and 2021 was retrospectively reviewed. A total of 32 patients with recurrent MTC and suspicious LN who underwent FNA and Ct measurement from washout samples were included in this study. Preoperative serum Ct (sCt), Ct-FNA, Ct-FNA/sCt ratio, cytology data were recorded for all participants. Results: Median sCt of 32 patients and Ct-FNA washout fluid levels of operated suspicious 44 LNs were 723 (54–9000) pg/mL and 1800 (151–9500) pg/mL, respectively. The diagnostic accuracy of Ct-FNA washout fluid was greater than cytology (95.4% vs. 86%, respectively). Using a cut-off level of >638.5 pg/mL, the Ct-FNA predicted the diagnosis of LN metastasis of recurrent MTC with a sensitivity of 80% and specificity of 94.9%. Furthermore, using a cut-off level of >1.16, the Ct-FNA/sCt ratio well predicted the diagnosis of LN metastasis of recurrent MTC with a sensitivity of 92.3% and specificity of 100%. Conclusion: As Ct-FNA has greater diagnostic accuracy in our study, it would be complementary to cytology results to localize metastatic LNs in recurrent MTC. Furthermore, for the first time, we demonstrated that the Ct-FNA/sCt ratio was a better predictor of metastatic LNs in recurrent MTC than a particular cut-off for Ct-FNA alone.Key words: Recurrent medullary thyroid cancer, fine needle aspiration cytology, calcitonin, washout sample

🔖

Cite This Article

CANPOLAT, A. G., ÇORAPÇIOĞLU, D., ŞAHİN, M., DEMİR, Ö., CEYHAN, K., EMRAL, R., ERDOĞAN, M. F., GÜLLÜ, S., SAK, S. (2022). Calcitonin levels in washout samples vs. cytology in the detection of malignant lymph node metastasis in recurrent medullary thyroid cancer. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 6, 3061–3066. https://ajindex.com/articles/609929

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Boi F, Maurelli I, Pinna G, Atzeni F, Piga M et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2007
  2. 92(6):2115-2118. doi: 10.1210/jc.2007-0326 2. Torresan F, Cavedon E, Mian C, Iacobone M. Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience. World Journal Surgery 2018
  3. 42(2):367-375. doi: 10.1007/s00268-017-4321-z 3. Rowland KJ, Jin LX, Moley JF. Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Annals of Surgical Oncology 2015
  4. 22(1):96-102. doi: 10.1245/ s10434-014-4102-y 4. Jin LX, Moley JF. Surgery for lymph node metastases of medullary thyroid carcinoma: A review. Cancer 2016
  5. 122(3):358-366. doi: 10.1002/cncr.29761 5. Stamatakos M, Paraskeva P, Stefanaki C, Katsaronis P, Lazaris A et al. Medullary thyroid carcinoma: The third most common thyroid cancer reviewed. Oncology Letters 2011
  6. 2(1):49-53. doi: 10.3892/ol.2010.223 6. Randle RW, Balentine CJ, Leverson GE, Havlena JA, Sippel RS et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 2017
  7. 161(1):137-146. doi: 10.1016/j.surg.2016.04.053 7. de Crea C, Raffaelli M, Maccora D, Carrozza C, Canu G et al. Calcitonin measurement in fine-needle aspirate washouts vs. cytologic examination for diagnosis of primary or metastatic medullary thyroid carcinoma. Acta Otorhinolaryngolica Italica 2014
  8. 34(6):399-405 8. Kihara M, Hirokawa M, Kudo T, Hayashi T, Yamamoto M et al. Calcitonin measurement in fine-needle aspirate washout fluid by electrochemiluminescence immunoassay for thyroid tumors. Thyroid Research 2018
  9. doi: 10.1186/s13044- 018-0059-4 9. Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clinical Endocrinology (Oxf) 2015
  10. 82(2):280-285. doi: 10.1111/cen.12563 10. Trimboli P, Guidobaldi L, Bongiovanni M, Crescenzi A, Alevizaki M et al. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review. Diagnostic Cytopathology 2016
  11. 44(1):45-51. doi: 10.1002/ dc.23375 11. Wells SA, Jr., Asa SL, Dralle H, Elisei R, Evans DB et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015
  12. 25(6):567-610. doi: 10.1089/t